<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7369591\results\search\disease\results.xml">
  <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
  <result pre="the COVID-19 resource centre remains active. Abstract The novel severe" exact="acute" post="respiratory syndrome coronavirus 2, the causal agent of coronavirus"/>
  <result pre="COVID-19 resource centre remains active. Abstract The novel severe acute" exact="respiratory" post="syndrome coronavirus 2, the causal agent of coronavirus disease"/>
  <result pre="resource centre remains active. Abstract The novel severe acute respiratory" exact="syndrome" post="coronavirus 2, the causal agent of coronavirus disease 2019"/>
  <result pre="acute respiratory syndrome coronavirus 2, the causal agent of coronavirus" exact="disease" post="2019 (COVID-19), quickly spread around the world, resulting in"/>
  <result pre="therapeutics are showing promise: those with antiviral activity directly addressing" exact="infection" post="and those that counteract the inflammatory cytokine storm induced"/>
  <result pre="for promising therapies is described. Abbreviations and Acronyms COVID-19, coronavirus" exact="disease" post="2019 CPT, convalescent plasma therapy CQ, chloroquine EC50, half-maximal"/>
  <result pre="interleukin 6 JAK, Janus kinase LPV/RTV, lopinavir/ritonavir MERS, Middle East" exact="respiratory" post="syndrome RCT, randomized controlled trial SARS, severe acute respiratory"/>
  <result pre="6 JAK, Janus kinase LPV/RTV, lopinavir/ritonavir MERS, Middle East respiratory" exact="syndrome" post="RCT, randomized controlled trial SARS, severe acute respiratory syndrome"/>
  <result pre="Middle East respiratory syndrome RCT, randomized controlled trial SARS, severe" exact="acute" post="respiratory syndrome SARS-CoV-2, severe acute respiratory syndrome coronavirus 2"/>
  <result pre="East respiratory syndrome RCT, randomized controlled trial SARS, severe acute" exact="respiratory" post="syndrome SARS-CoV-2, severe acute respiratory syndrome coronavirus 2 WHO,"/>
  <result pre="respiratory syndrome RCT, randomized controlled trial SARS, severe acute respiratory" exact="syndrome" post="SARS-CoV-2, severe acute respiratory syndrome coronavirus 2 WHO, World"/>
  <result pre="randomized controlled trial SARS, severe acute respiratory syndrome SARS-CoV-2, severe" exact="acute" post="respiratory syndrome coronavirus 2 WHO, World Health Organization Article"/>
  <result pre="controlled trial SARS, severe acute respiratory syndrome SARS-CoV-2, severe acute" exact="respiratory" post="syndrome coronavirus 2 WHO, World Health Organization Article Highlights"/>
  <result pre="trial SARS, severe acute respiratory syndrome SARS-CoV-2, severe acute respiratory" exact="syndrome" post="coronavirus 2 WHO, World Health Organization Article Highlights â€¢Most"/>
  <result pre="World Health Organization Article Highlights â€¢Most emerging therapies for coronavirus" exact="disease" post="2019 have antiviral activity for addressing infection directly or"/>
  <result pre="therapies for coronavirus disease 2019 have antiviral activity for addressing" exact="infection" post="directly or counteract the inflammatory cytokine storm induced by"/>
  <result pre="disease. â€¢The currently available clinical evidence for promising emerging coronavirus" exact="disease" post="2019 therapies provides rationale for continued investigation but is"/>
  <result pre="will be essential for measuring their efficacy. The novel severe" exact="acute" post="respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2), the causal agent"/>
  <result pre="be essential for measuring their efficacy. The novel severe acute" exact="respiratory" post="syndrome (SARS) coronavirus 2 (SARS-CoV-2), the causal agent of"/>
  <result pre="essential for measuring their efficacy. The novel severe acute respiratory" exact="syndrome" post="(SARS) coronavirus 2 (SARS-CoV-2), the causal agent of coronavirus"/>
  <result pre="syndrome (SARS) coronavirus 2 (SARS-CoV-2), the causal agent of coronavirus" exact="disease" post="2019 (COVID-19), appeared in December 2019 in Wuhan, China,"/>
  <result pre="emergent pandemic threats has been largely reactive because of the" exact="absence of" post="established therapeutic interventions.4 In a pandemic, there are inherent"/>
  <result pre="that were used for similar diseases including SARS, Middle East" exact="respiratory" post="syndrome (MERS), and Ebola have emerged as treatment options"/>
  <result pre="were used for similar diseases including SARS, Middle East respiratory" exact="syndrome" post="(MERS), and Ebola have emerged as treatment options because"/>
  <result pre="therapies identified in a LitCovid literature hub search of 5788" exact="total" post="publications is reviewed below and summarized in TableÂ 1"/>
  <result pre="of RNA synthesis Antiviral Favipiravir Preclinical: 12Clinical trial: 25, 26b" exact="Selective" post="inhibition of RNA polymerase Antiviral Lopinavir/ritonavir Preclinical: 10Case series:"/>
  <result pre="40, 79, 80, 85, 86, 87, 94,b 97 Inhibition of" exact="viral" post="replication and modulation of immune responses Antiviral/anti-inflammatory Convalescent plasma"/>
  <result pre="Transfer of humoral immunity Antiâ€&quot;SARS-CoV-2 humoral immunity aCOVID-19Â = coronavirus" exact="disease" post="2019; SARS-CoV-2Â = severe acute respiratory distress syndrome coronavirusÂ"/>
  <result pre="humoral immunity aCOVID-19Â = coronavirus disease 2019; SARS-CoV-2Â = severe" exact="acute" post="respiratory distress syndrome coronavirusÂ 2. bNonâ€&quot;peer-reviewed publications. Remdesivir Remdesivir"/>
  <result pre="immunity aCOVID-19Â = coronavirus disease 2019; SARS-CoV-2Â = severe acute" exact="respiratory" post="distress syndrome coronavirusÂ 2. bNonâ€&quot;peer-reviewed publications. Remdesivir Remdesivir is"/>
  <result pre="= coronavirus disease 2019; SARS-CoV-2Â = severe acute respiratory distress" exact="syndrome" post="coronavirusÂ 2. bNonâ€&quot;peer-reviewed publications. Remdesivir Remdesivir is an adenosine"/>
  <result pre="developed to treat Ebola. Its effects derive from inhibition of" exact="viral" post="replication and RNA synthesis.8,9 Data supporting treatment of SARS-CoV-2"/>
  <result pre="viral replication and RNA synthesis.8,9 Data supporting treatment of SARS-CoV-2" exact="infection" post="with remdesivir include established potency against coronaviruses inÂ vitro8"/>
  <result pre="half-maximal effective concentration (EC50) of 0.77 Î¼M and inhibition of" exact="infection" post="in Huh-7 cells.12 Combination with emetine may enhance viral"/>
  <result pre="of infection in Huh-7 cells.12 Combination with emetine may enhance" exact="viral" post="inhibition.13 Clinically, multiple case reports and series from Canada,"/>
  <result pre="1063 patients, funded by the National Institute of Allergy and" exact="Infectious" post="Diseases, reported an 11-day median recovery time compared with"/>
  <result pre="Favipiravirâ€™s antiviral properties are thought to arise from inhibition of" exact="viral" post="RNA polymerase, halting the replication cycle.23,24 Reports on favipiravirâ€™s"/>
  <result pre="the replication cycle.23,24 Reports on favipiravirâ€™s efficacy in COVID-19 are" exact="limited" post="to inÂ vitro studies determining an EC50 of 61.88"/>
  <result pre="91.43% of the 35 patients receiving favipiravir exhibited improvement in" exact="chest" post="imaging and had a median time of viral clearance"/>
  <result pre="improvement in chest imaging and had a median time of" exact="viral" post="clearance of 4 days compared with 62.2% (P=.004) of"/>
  <result pre="(P=.004) of the 45 patients receiving LPV/RTV exhibiting improvement in" exact="chest" post="imaging and a median of 11 days for viral"/>
  <result pre="in chest imaging and a median of 11 days for" exact="viral" post="clearance (P&amp;lt;.001). The randomized multicenter trial reported a 7-day"/>
  <result pre="a 7-day clinical recovery rate (&amp;gt;72 hours normalization of temperature," exact="respiratory" post="rate, oxygen saturation, and cough) of 71.43% and 55.86%"/>
  <result pre="71.43% and 55.86% (P=.0199) for patients with mild or moderate" exact="disease" post="treated with favipiravir or arbidol, respectively, but no difference"/>
  <result pre="but no difference in critically ill patients or those with" exact="hypertension" post="and/or diabetes (P=.4712 and P=.7704). Lopinavir/Ritonavir Lopinavir/ritonavir inhibit the"/>
  <result pre="difference in critically ill patients or those with hypertension and/or" exact="diabetes" post="(P=.4712 and P=.7704). Lopinavir/Ritonavir Lopinavir/ritonavir inhibit the human immunodeficiency"/>
  <result pre="and/or diabetes (P=.4712 and P=.7704). Lopinavir/Ritonavir Lopinavir/ritonavir inhibit the human" exact="immunodeficiency" post="virus type 1 protease and are used in the"/>
  <result pre="(P=.4712 and P=.7704). Lopinavir/Ritonavir Lopinavir/ritonavir inhibit the human immunodeficiency virus" exact="type 1" post="protease and are used in the treatment of human"/>
  <result pre="1 protease and are used in the treatment of human" exact="immunodeficiency" post="virus infection and AIDS. Reports of the potentially successful"/>
  <result pre="protease and are used in the treatment of human immunodeficiency" exact="virus infection" post="and AIDS. Reports of the potentially successful use of"/>
  <result pre="and are used in the treatment of human immunodeficiency virus" exact="infection" post="and AIDS. Reports of the potentially successful use of"/>
  <result pre="model of MERS, LPV/RTV was able to only slightly reduce" exact="viral" post="load without impacting other disease parameters.10 Preliminary clinical data"/>
  <result pre="able to only slightly reduce viral load without impacting other" exact="disease" post="parameters.10 Preliminary clinical data on LPV/RTV therapy in patients"/>
  <result pre="patients resulted in a shorter median number of days to" exact="viral" post="clearance (7 vs 12 (P=.0010) in patients treated with"/>
  <result pre="or no antiviral therapy revealed no improvement in symptoms or" exact="viral" post="clearance from treatment (P&amp;gt;.05).36,37 A 199-patient RCT of LPV/RTV"/>
  <result pre="in no benefit in time to clinical improvement (P=.09) or" exact="viral" post="RNA load compared with controls but did report reduced"/>
  <result pre="including decreased mortality and shorter hospital stay, of properly prescribed" exact="systemic" post="glucocorticoid therapy for critically ill patients with SARS,52,53 glucocorticoid"/>
  <result pre="multicenter study of 63 patients receiving tocilizumab reported improvement in" exact="respiratory" post="and laboratory parameters. In this same study, administration of"/>
  <result pre="patients receiving tocilizumab suggested that IL-6 levels in patients with" exact="hyperglycemia" post="persisted at levels 5-fold higher than those in patients"/>
  <result pre="vitro experiments establishing the JAK inhibitor baricitinibâ€™s ability to reduce" exact="viral" post="load in human primary liver spheroids and a 4-patient"/>
  <result pre="JAK inhibitor baricitinibâ€™s ability to reduce viral load in human" exact="primary" post="liver spheroids and a 4-patient case series exhibiting improvement"/>
  <result pre="in signs and symptoms including cough, fever, IL-6 level, and" exact="viral" post="load seem to validate its identification as a potential"/>
  <result pre="in 12 Italian patients resulted in improvements in clinical and" exact="respiratory" post="parameters in the following 2 weeks.63 A retrospective multicenter"/>
  <result pre="analogues that have been widely used in the treatment of" exact="malaria" post="and autoimmune diseases such as rheumatoid arthritis and systemic"/>
  <result pre="have been widely used in the treatment of malaria and" exact="autoimmune diseases" post="such as rheumatoid arthritis and systemic lupus erythematosus. Their"/>
  <result pre="in the treatment of malaria and autoimmune diseases such as" exact="rheumatoid arthritis" post="and systemic lupus erythematosus. Their inÂ vitro antiviral properties"/>
  <result pre="the treatment of malaria and autoimmune diseases such as rheumatoid" exact="arthritis" post="and systemic lupus erythematosus. Their inÂ vitro antiviral properties"/>
  <result pre="of malaria and autoimmune diseases such as rheumatoid arthritis and" exact="systemic" post="lupus erythematosus. Their inÂ vitro antiviral properties have been"/>
  <result pre="malaria and autoimmune diseases such as rheumatoid arthritis and systemic" exact="lupus erythematosus." post="Their inÂ vitro antiviral properties have been known for"/>
  <result pre="CQ has failed to translate to clinical outcomes in other" exact="viral" post="diseases (reviewed in reference 73). Double-blind RCTs to date"/>
  <result pre="of HCQ in China reported no difference in time to" exact="viral" post="clearance, body temperature, or radiological progression compared to conventional"/>
  <result pre="describing a 150-patient open-label RCT also reported no difference in" exact="viral" post="clearance through 28 days between patients treated with HCQ"/>
  <result pre="80 additional French patients with COVID-19 confirmed considerable reductions in" exact="viral" post="load and improved clinical outcomes,87 the first study has"/>
  <result pre="patients dropped from analysis, and the chosen thresholds for determining" exact="viral" post="presence.88,89 A statement from the International Society of Antimicrobial"/>
  <result pre="their expected standards.90 Interestingly, a separate teamâ€™s efforts to replicate" exact="viral" post="clearance in a 12-patient case series using HCQ/azithromycin combination"/>
  <result pre="a good clinical outcome (no death, hospitalization for â‰¥10 days," exact="viral" post="shedding, or transfer to the ICU) in 91.7% of"/>
  <result pre="double-blind RCT of HCQ therapy in 62 patients with mild" exact="disease" post="also seem to indicate some benefit in time to"/>
  <result pre="in-hospital mortality was retracted when a full audit of the" exact="primary" post="dataset could not be completed.95 As a result of"/>
  <result pre="is currently under peer review suggests that for patients with" exact="pneumonia" post="as the primary source of sepsis, this approach may"/>
  <result pre="peer review suggests that for patients with pneumonia as the" exact="primary" post="source of sepsis, this approach may improve mortality rates.102"/>
  <result pre="made CPT available for use in patients with serious COVID-19" exact="infections" post="through emergency investigational new drug applications.103 Actual data on"/>
  <result pre="improvement due to CPT, ranging from improvement in laboratory and" exact="respiratory" post="parameters without change in overall status to improvements in"/>
  <result pre="respiratory parameters without change in overall status to improvements in" exact="viral" post="clearance and status as determined by the WHO ordinal"/>
  <result pre="CPT compared with 43.1% in the control group (P=.26), but" exact="viral" post="clearance was achieved in 87.2% of patients in the"/>
  <result pre="low-dose radiation therapy to suppress the cytokine storm and resultant" exact="pulmonary" post="inflammation and edema118 as well as evaluation of ivermectin"/>
  <result pre="0 (0) Multi 1 (8) Other 838 aCOVID-19 = coronavirus" exact="disease" post="2019; SARS-CoV-2 = severe acute respiratory distress syndrome coronavirus"/>
  <result pre="Other 838 aCOVID-19 = coronavirus disease 2019; SARS-CoV-2 = severe" exact="acute" post="respiratory distress syndrome coronavirus 2; 2019-nCoV = 2019 novel"/>
  <result pre="838 aCOVID-19 = coronavirus disease 2019; SARS-CoV-2 = severe acute" exact="respiratory" post="distress syndrome coronavirus 2; 2019-nCoV = 2019 novel coronavirus."/>
  <result pre="= coronavirus disease 2019; SARS-CoV-2 = severe acute respiratory distress" exact="syndrome" post="coronavirus 2; 2019-nCoV = 2019 novel coronavirus. bTotal recruiting/open"/>
  <result pre="WHO-sponsored, adaptive RCT open to any patient with confirmed SARS-CoV-2" exact="infection" post="worldwide. On the basis of institutional drug availability, patients"/>
  <result pre="Outcomes Related to COVID-19 treated with hydroxychloroquine among in-patients with" exact="symptomatic" post="Disease study (ORCHID) was halted after the data safety"/>
  <result pre="Related to COVID-19 treated with hydroxychloroquine among in-patients with symptomatic" exact="Disease" post="study (ORCHID) was halted after the data safety and"/>
  <result pre="y and hospitalized with confirmed COVID-19Â + SpO2 â‰¤94% or" exact="acute" post="respiratory failure Clinical status at day 15Hospital length of"/>
  <result pre="and hospitalized with confirmed COVID-19Â + SpO2 â‰¤94% or acute" exact="respiratory" post="failure Clinical status at day 15Hospital length of stayMortality"/>
  <result pre="ventilation Hydroxychloroquine Versus Placebo in COVID-19 Patients at Risk for" exact="Severe" post="Disease (HYCOVID) (ClinicalTrials.gov identifier: NCT04325893) France (1300) University Hospital"/>
  <result pre="Hydroxychloroquine Versus Placebo in COVID-19 Patients at Risk for Severe" exact="Disease" post="(HYCOVID) (ClinicalTrials.gov identifier: NCT04325893) France (1300) University Hospital Angers"/>
  <result pre="or SpO2 â‰¤94% or FiO2 â‰¤300 mm HgElectrocardiogram showing the" exact="absence of" post="QT interval prolongation Mortality or need for intubation and"/>
  <result pre="(ClinicalTrials.gov identifier: NCT04280705) Global (440) National Institute of Allergy and" exact="Infectious" post="Diseases Remdesivir Placebo Phase III, multicenter, adaptive, double-blind RCT"/>
  <result pre="identifier: NCT04280705) Global (440) National Institute of Allergy and Infectious" exact="Diseases" post="Remdesivir Placebo Phase III, multicenter, adaptive, double-blind RCT â‰¥18"/>
  <result pre="Evaluate the Safety and Efficacy of Tocilizumab in Patients With" exact="Severe" post="COVID-19 Pneumonia (COVACTA) (ClinicalTrials.gov identifier: NCT04320615) Global (330) Hoffmann-La"/>
  <result pre="Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19" exact="Pneumonia" post="(COVACTA) (ClinicalTrials.gov identifier: NCT04320615) Global (330) Hoffmann-La Roche Tocilizumab"/>
  <result pre="28, and 60-d mortality Convalescent Plasma as Therapy for Covid-19" exact="Severe" post="SARS-CoV-2 Disease (CONCOVID Study) (ClinicalTrials.gov identifier: NCT04342182) The Netherlands"/>
  <result pre="60-d mortality Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2" exact="Disease" post="(CONCOVID Study) (ClinicalTrials.gov identifier: NCT04342182) The Netherlands (426) Erasmus"/>
  <result pre="hospital discharge or 60-dHospital length of stay COVID-19Â = coronavirus" exact="disease" post="2019; CQ/HCQÂ = chloroquine or hydroxychloroquine; FiO2Â = fraction"/>
  <result pre="care unit; IFNÂ = interferon; LPV/RTVÂ = lopinavir/ritonavir; PaO2Â =" exact="partial" post="pressure of oxygen; RCTÂ = randomized controlled trial; SoCÂ"/>
  <result pre="randomized controlled trial; SoCÂ = standard of care; SpO2Â =" exact="peripheral" post="capillary oxygen saturation. Conclusion This review of available data"/>
  <result pre="reports of the use of convalescent plasma, usually in late-stage" exact="disease" post="and after other treatments, provide some support for clinical"/>
  <result pre="need of effective treatments and cures such as cancer, obesity," exact="Alzheimer" post="disease, diabetes, or opioid and alcohol addiction. The COVID-19"/>
  <result pre="2020 3DengY.LiuW.LiuK.Clinical characteristics of fatal and recovered cases of coronavirus" exact="disease" post="2019 (COVID-19) in Wuhan, China: a retrospective studyChin Med"/>
  <result pre="in Wuhan, China: a retrospective studyChin Med J (Engl)1331120201261126732209890 4GrahamB.S.SullivanN.J.Emerging" exact="viral" post="diseases from a vaccinology perspective: preparing for the next"/>
  <result pre="Studies found for: COVID-19. https://clinicaltrials.gov/ct2/results?cond=COVID-19. Accessed June 29, 2020. 8AgostiniM.L.AndresE.L.SimsA.C.Coronavirus" exact="susceptibility to" post="the antiviral remdesivir (GS-5734) is mediated by the viral"/>
  <result pre="susceptibility to the antiviral remdesivir (GS-5734) is mediated by the" exact="viral" post="polymerase and the proofreading exoribonucleasemBio922018e00221-e00218 9TchesnokovE.P.FengJ.Y.PorterD.P.GÃ¶tteM.Mechanism of inhibition of"/>
  <result pre="a COVID-19 positive patientPharmacotherapy406202059259832281114 16Durante-MangoniE.AndiniR.BertolinoL.Early experience with remdesivir in SARS-CoV-2" exact="pneumonia" post="[published online ahead of print May 16, 2020]Infectionhttps://doi.org/10.1007/s15010-020-01448-x 17collab:"/>
  <result pre="and virologic characteristics of the first 12 patients with coronavirus" exact="disease" post="2019 (COVID-19) in the United StatesNat Med266202086186832327757 18AntinoriS.CossuM.V.RidolfoA.L.Compassionate remdesivir"/>
  <result pre="the United StatesNat Med266202086186832327757 18AntinoriS.CossuM.V.RidolfoA.L.Compassionate remdesivir treatment of severe Covid-19" exact="pneumonia" post="in intensive care unit (ICU) and non-ICU patients: clinical"/>
  <result pre="Engl J Medhttps://doi.org/10.1056/NEJMoa2015301 23FurutaY.KomenoT.NakamuraT.Favipiravir (T-705), a broad spectrum inhibitor of" exact="viral" post="RNA polymeraseProc Japn Acad Ser B Phys Biol Sci9372017449463"/>
  <result pre="27KimU.J.WonE.J.KeeS.J.JungS.I.JangH.C.Combination therapy with lopinavir/ritonavir, ribavirin and interferon-Î± for Middle East" exact="respiratory" post="syndromeAntivir Ther215201645545926492219 28SpanakisN.TsiodrasS.HaagmansB.L.Virological and serological analysis of a recent"/>
  <result pre="Ther215201645545926492219 28SpanakisN.TsiodrasS.HaagmansB.L.Virological and serological analysis of a recent Middle East" exact="respiratory" post="syndrome coronavirus infection case on a triple combination antiviral"/>
  <result pre="28SpanakisN.TsiodrasS.HaagmansB.L.Virological and serological analysis of a recent Middle East respiratory" exact="syndrome" post="coronavirus infection case on a triple combination antiviral regimenInt"/>
  <result pre="serological analysis of a recent Middle East respiratory syndrome coronavirus" exact="infection" post="case on a triple combination antiviral regimenInt J Antimicrob"/>
  <result pre="J Antimicrob Agents446201452853225288266 29ArabiY.M.AlothmanA.BalkhyH.H.collab: MIRACLE trial groupTreatment of Middle East" exact="Respiratory" post="Syndrome with a combination of lopinavir-ritonavir and interferon-Î²1b (MIRACLE"/>
  <result pre="Antimicrob Agents446201452853225288266 29ArabiY.M.AlothmanA.BalkhyH.H.collab: MIRACLE trial groupTreatment of Middle East Respiratory" exact="Syndrome" post="with a combination of lopinavir-ritonavir and interferon-Î²1b (MIRACLE trial):"/>
  <result pre="and therapeutic procedure for four cases with 2019 novel coronavirus" exact="pneumonia" post="receiving combined Chinese and Western medicine treatmentBiosci Trends1412020646832037389 31YoungB.E.OngS.W.X.KalimuddinS.collab:"/>
  <result pre="outcome of COVID-19 progressionInt J Infect Dis95202018319132173576 33YuanJ.ZouR.ZengL.The correlation between" exact="viral" post="clearance and biochemical outcomes of 94 COVID-19 infected discharged"/>
  <result pre="Res696202059960632227274 34YeX.T.LuoY.L.XiaS.C.Clinical efficacy of lopinavir/ritonavir in the treatment of coronavirus" exact="disease" post="2019Eur Rev Med Pharmacol Sci24620203390339632271456 35HungI.F.N.LungK.C.TsoE.Y.K.Triple combination of interferon"/>
  <result pre="et al. Efficacy and safety of lopinavir/ritonavir or arbidol in" exact="adult" post="patients with mild/moderate COVID-19: an exploratory randomized controlled trial"/>
  <result pre="41SchoergenhoferC.JilmaB.StimpflT.KarolyiM.ZoufalyA.Pharmacokinetics of lopinavir and ritonavir in patients hospitalized with coronavirus" exact="disease" post="2019 (COVID-19) [published online ahead of print May 12,"/>
  <result pre="2020]Ann Intern Medhttps://doi.org/10.7326/M20-1550 42WongC.K.LamC.W.K.WuA.K.L.Plasma inflammatory cytokines and chemokines in severe" exact="acute" post="respiratory syndromeClin Exp Immunol136120049510315030519 43HuangC.WangY.LiX.Clinical features of patients infected"/>
  <result pre="Intern Medhttps://doi.org/10.7326/M20-1550 42WongC.K.LamC.W.K.WuA.K.L.Plasma inflammatory cytokines and chemokines in severe acute" exact="respiratory" post="syndromeClin Exp Immunol136120049510315030519 43HuangC.WangY.LiX.Clinical features of patients infected with"/>
  <result pre="and clinical characteristics of 99 cases of 2019 novel coronavirus" exact="pneumonia" post="in Wuhan, China: a descriptive studyLancet39510233202050751332007143 45WanS.YiQ.FanS.Characteristics of lymphocyte"/>
  <result pre="a descriptive studyLancet39510233202050751332007143 45WanS.YiQ.FanS.Characteristics of lymphocyte subsets and cytokines in" exact="peripheral" post="blood of 123 hospitalized patients with 2019 novel coronavirus"/>
  <result pre="peripheral blood of 123 hospitalized patients with 2019 novel coronavirus" exact="pneumonia" post="(NCP) [published online ahead of print February 12, 2020]medRxivhttps://doi.org/10.1101/2020.02.10.20021832"/>
  <result pre="online ahead of print February 12, 2020]medRxivhttps://doi.org/10.1101/2020.02.10.20021832 46ChenX.ZhaoB.QuY.Detectable serum SARS-CoV-2" exact="viral" post="load (RNAaemia) is closely correlated with drastically elevated interleukin"/>
  <result pre="COVID-19 in Wuhan, ChinaClin Infect Dis7115202076276832161940 48ShiY.TanM.ChenX.Immunopathological characteristics of coronavirus" exact="disease" post="2019 cases in Guangzhou, China [published online ahead of"/>
  <result pre="print March 16, 2020]medRxivhttps://doi.org/10.1101/2020.03.12.20034736 49RichardsonP.GriffinI.TuckerC.Baricitinib as potential treatment for 2019-nCoV" exact="acute" post="respiratory diseaseLancet395102232020e30e3132032529 50StebbingJ.PhelanA.GriffinI.COVID-19: combining antiviral and anti-inflammatory treatmentsLancet Infect"/>
  <result pre="March 16, 2020]medRxivhttps://doi.org/10.1101/2020.03.12.20034736 49RichardsonP.GriffinI.TuckerC.Baricitinib as potential treatment for 2019-nCoV acute" exact="respiratory" post="diseaseLancet395102232020e30e3132032529 50StebbingJ.PhelanA.GriffinI.COVID-19: combining antiviral and anti-inflammatory treatmentsLancet Infect Dis204202040040232113509"/>
  <result pre="for management of COVID-19Int J Antimicrob Agents555202010596732259575 52ChenR.C.TangX.P.TanS.Y.Treatment of severe" exact="acute" post="respiratory syndrome with glucosteroids: the Guangzhou experienceChest129620061441145216778260 53SungJ.J.Y.WuA.JoyntG.M.Severe acute"/>
  <result pre="management of COVID-19Int J Antimicrob Agents555202010596732259575 52ChenR.C.TangX.P.TanS.Y.Treatment of severe acute" exact="respiratory" post="syndrome with glucosteroids: the Guangzhou experienceChest129620061441145216778260 53SungJ.J.Y.WuA.JoyntG.M.Severe acute respiratory"/>
  <result pre="of COVID-19Int J Antimicrob Agents555202010596732259575 52ChenR.C.TangX.P.TanS.Y.Treatment of severe acute respiratory" exact="syndrome" post="with glucosteroids: the Guangzhou experienceChest129620061441145216778260 53SungJ.J.Y.WuA.JoyntG.M.Severe acute respiratory syndrome:"/>
  <result pre="severe acute respiratory syndrome with glucosteroids: the Guangzhou experienceChest129620061441145216778260 53SungJ.J.Y.WuA.JoyntG.M.Severe" exact="acute" post="respiratory syndrome: report of treatment and outcome after a"/>
  <result pre="acute respiratory syndrome with glucosteroids: the Guangzhou experienceChest129620061441145216778260 53SungJ.J.Y.WuA.JoyntG.M.Severe acute" exact="respiratory" post="syndrome: report of treatment and outcome after a major"/>
  <result pre="J Intern Med762020313532405160 58ToniatiP.PivaS.CattaliniM.Tocilizumab for the treatment of severe COVID-19" exact="pneumonia" post="with hyperinflammatory syndrome and acute respiratory failure: a single"/>
  <result pre="58ToniatiP.PivaS.CattaliniM.Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory" exact="syndrome" post="and acute respiratory failure: a single center study of"/>
  <result pre="the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and" exact="acute" post="respiratory failure: a single center study of 100 patients"/>
  <result pre="treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute" exact="respiratory" post="failure: a single center study of 100 patients in"/>
  <result pre="multicenter study on the impact of baricitinib in COVID-19 moderate" exact="pneumonia" post="[published online ahead of print June 24, 2020]J Infecthttps://doi.org/10.1016/j.jinf.2020.06.052"/>
  <result pre="June 24, 2020]J Infecthttps://doi.org/10.1016/j.jinf.2020.06.052 65CaoY.WeiJ.ZouL.Ruxolitinib in treatment of severe coronavirus" exact="disease" post="2019 (COVID-19): a multicenter, single-blind, randomized controlled trialJÂ Allergy"/>
  <result pre="RosÃ©eF.BremerH.C.GehrkeI.The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe" exact="systemic" post="hyperinflammationLeukemia34720201805181532518419 67LuS.ZhouQ.HuangL.Effectiveness and safety of glucocorticoids to treat COVID-19:"/>
  <result pre="animal virusesArch Gesamte Virusforsch3611972931044335025 72KeyaertsE.VijgenL.MaesP.NeytsJ.Van RanstV.InÂ vitro inhibition of severe" exact="acute" post="respiratory syndrome coronavirus by chloroquineBiochem Biophys Res Commun3231200426426815351731 73TouretF.de"/>
  <result pre="virusesArch Gesamte Virusforsch3611972931044335025 72KeyaertsE.VijgenL.MaesP.NeytsJ.Van RanstV.InÂ vitro inhibition of severe acute" exact="respiratory" post="syndrome coronavirus by chloroquineBiochem Biophys Res Commun3231200426426815351731 73TouretF.de LamballerieX.Of"/>
  <result pre="Gesamte Virusforsch3611972931044335025 72KeyaertsE.VijgenL.MaesP.NeytsJ.Van RanstV.InÂ vitro inhibition of severe acute respiratory" exact="syndrome" post="coronavirus by chloroquineBiochem Biophys Res Commun3231200426426815351731 73TouretF.de LamballerieX.Of chloroquine"/>
  <result pre="PLoS Negl Trop Dis. 2012;6(6)]PLoS Negl Trop Dis482010e78520706626 76De LamballerieX.BoissonV.ReynierJ.C.On" exact="chikungunya" post="acute infection and chloroquine treatmentVector Borne jDis862008837840 77LiuJ.CaoR.XuM.Hydroxychloroquine, a"/>
  <result pre="Negl Trop Dis. 2012;6(6)]PLoS Negl Trop Dis482010e78520706626 76De LamballerieX.BoissonV.ReynierJ.C.On chikungunya" exact="acute" post="infection and chloroquine treatmentVector Borne jDis862008837840 77LiuJ.CaoR.XuM.Hydroxychloroquine, a less"/>
  <result pre="Trop Dis. 2012;6(6)]PLoS Negl Trop Dis482010e78520706626 76De LamballerieX.BoissonV.ReynierJ.C.On chikungunya acute" exact="infection" post="and chloroquine treatmentVector Borne jDis862008837840 77LiuJ.CaoR.XuM.Hydroxychloroquine, a less toxic"/>
  <result pre="less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2" exact="infection" post="inÂ vitroCell Discov620201632194981 78YaoX.YeF.ZhangM.InÂ vitro antiviral activity and projection"/>
  <result pre="optimized dosing design of hydroxychloroquine for the treatment of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2)Clin Infect Dis7115202073273932150618 79ChenJ.LiuD.LiuL.AÂ pilot"/>
  <result pre="dosing design of hydroxychloroquine for the treatment of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2)Clin Infect Dis7115202073273932150618 79ChenJ.LiuD.LiuL.AÂ pilot study"/>
  <result pre="design of hydroxychloroquine for the treatment of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2)Clin Infect Dis7115202073273932150618 79ChenJ.LiuD.LiuL.AÂ pilot study of"/>
  <result pre="Sci)4922020215219 80TangW.CaoZ.HanM.Hydroxychloroquine in patients with mainly mild to moderate coronavirus" exact="disease" post="2019: open label, randomised controlled trialBMJ3692020m184932409561 81MagagnoliJ.NarendranS.PereiraF.Outcomes of hydroxychloroquine"/>
  <result pre="21, 2020]medRxivhttps://doi.org/10.1101/2020.04.16.20065920 82MahÃ©vasM.TranV.T.RoumierM.Clinical efficacy of hydroxychloroquine in patients with covid-19" exact="pneumonia" post="who require oxygen: observational comparative study using routine care"/>
  <result pre="den BroekM.P.H.MÃ¶hlmannJ.E.AbelnB.G.S.LiebregtsM.van DijkV.F.van de GardeE.M.W.Chloroquine-induced QTc prolongation in COVID-19 patientsNeth." exact="Heart" post="J287-8202040640932350818 97BunS.-S.TaghjiP.CourjonJ.QT interval prolongation under hydroxychloroquine/azithromycin association for inpatients"/>
  <result pre="97BunS.-S.TaghjiP.CourjonJ.QT interval prolongation under hydroxychloroquine/azithromycin association for inpatients with SARS-CoV-2" exact="lower" post="respiratory tract infection [published online ahead of print June"/>
  <result pre="interval prolongation under hydroxychloroquine/azithromycin association for inpatients with SARS-CoV-2 lower" exact="respiratory" post="tract infection [published online ahead of print June 26,"/>
  <result pre="under hydroxychloroquine/azithromycin association for inpatients with SARS-CoV-2 lower respiratory tract" exact="infection" post="[published online ahead of print June 26, 2020]Clin Pharmacol"/>
  <result pre="chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical"/>
  <result pre="diphosphate as adjunctive therapy for patients hospitalized with severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trialJAMA"/>
  <result pre="as adjunctive therapy for patients hospitalized with severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trialJAMA Netw"/>
  <result pre="guided dosing for investigational treatments of pediatric patients with coronavirus" exact="disease" post="2019 [published online ahead of print June 5, 2020]JAMA"/>
  <result pre="105ZhangB.LiuS.TanT.Treatment with convalescent plasma for critically ill patients with severe" exact="acute" post="respiratory syndrome coronavirus 2 infectionChest15812020e9e1332243945 106YeM.FuD.RenY.Treatment with convalescent plasma"/>
  <result pre="with convalescent plasma for critically ill patients with severe acute" exact="respiratory" post="syndrome coronavirus 2 infectionChest15812020e9e1332243945 106YeM.FuD.RenY.Treatment with convalescent plasma for"/>
  <result pre="convalescent plasma for critically ill patients with severe acute respiratory" exact="syndrome" post="coronavirus 2 infectionChest15812020e9e1332243945 106YeM.FuD.RenY.Treatment with convalescent plasma for COVID-19"/>
  <result pre="107AhnJ.Y.SohnY.LeeS.H.Use of convalescent plasma therapy in two COVID-19 patients with" exact="acute" post="respiratory distress syndrome in KoreaJÂ Korean Med Sci35142020e14932281317 108DuanK.LiuB.LiC.Effectiveness"/>
  <result pre="of convalescent plasma therapy in two COVID-19 patients with acute" exact="respiratory" post="distress syndrome in KoreaJÂ Korean Med Sci35142020e14932281317 108DuanK.LiuB.LiC.Effectiveness of"/>
  <result pre="plasma therapy in two COVID-19 patients with acute respiratory distress" exact="syndrome" post="in KoreaJÂ Korean Med Sci35142020e14932281317 108DuanK.LiuB.LiC.Effectiveness of convalescent plasma"/>
  <result pre="pilot studyRev Invest Clin723202015916432584322 112ZengQ.-L.YuZ.-J.GouJ.-J.Effect of convalescent plasma therapy on" exact="viral" post="shedding and survival in patients with coronavirus disease 2019JÂ"/>
  <result pre="therapy on viral shedding and survival in patients with coronavirus" exact="disease" post="2019JÂ Infect Dis22212020384332348485 113LiL.ZhangW.HuY.Effect of convalescent plasma therapy on"/>
  <result pre="Company. Lilly Begins World's First Study of a Potential COVID-19" exact="Antibody" post="Treatment in Humans. Lilly website. https://investor.lilly.com/news-releases/news-release-details/lilly-begins-worlds-first-study-potential-covid-19-antibody. Published June 1,"/>
 </snippets>
</snippetsTree>
